Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons with HIV

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S12-S23

  MacBrayne, Christine E ^a   Kiser, Jennifer J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

coinfection; direct acting antivirals; drug interactions; hepatitis C virus; human immunodeficiency virus

Indexed keywords

ABC TRANSPORTER SUBFAMILY B; ATAZANAVIR; BECLABUVIR; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; COBICISTAT; CYCLOSPORINE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOKINE; DACLATASVIR; DARUNAVIR; DASABUVIR; DIGOXIN; DIRECT ACTING ANTIVIRAL AGENT; EFAVIRENZ; ELBASVIR; ELVITEGRAVIR; EMTRICITABINE; ENVELOPE PROTEIN; FAMOTIDINE; GLUCURONOSYLTRANSFERASE 1A1; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GRAZOPREVIR; GS 331007 INHIBITOR; GS 461203 INHIBITOR; HEMOGLOBIN; HEPACIVIRIN; KETOCONAZOLE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LANSOPRAZOLE; LEDIPASVIR; LOPINAVIR; MIDAZOLAM; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; OMEPRAZOLE; PARATHYROID HORMONE; PARITAPREVIR; PEGINTERFERON ALPHA2B; PLASMA BINDING PROTEIN; POLYPROTEIN; PRAVASTATIN; RALTEGRAVIR; RANITIDINE; RIBAVIRIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; ROSUVASTATIN; SIMEPREVIR; SMALL INTERFERING RNA; SOFOSBUVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; TEGOBUVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; TIPRANAVIR; UNCLASSIFIED DRUG; URIDINE MONOPHOSPHATE CYTIDINE MONOPHOSPHATE KINASE; VEDROPREVIR; VELPATASVIR; ANTIVIRUS AGENT;

AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; CHILD PUGH SCORE; CLINICAL PHARMACOLOGY; COINFECTION; DISEASE EXACERBATION; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FATIGUE; GENETIC TRANSCRIPTION; HEADACHE; HEMODIALYSIS; HEPATIC METABOLISM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAXIMUM CONCENTRATION; MILD HEPATIC IMPAIRMENT; NAUSEA; NONHUMAN; PH; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ACID; SUSTAINED VIROLOGIC RESPONSE; THERAPEUTIC INDEX; VIROLOGIC FAILURE; VIRUS REPLICATION; COMPLICATION; MIXED INFECTION; PRACTICE GUIDELINE;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84988373055     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw220     Document Type: Article

References (71)

1. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992–1002.
2. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999; 31(suppl 1):88–91.
3. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491–8.
4. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol 2014; 11:362–71.
5. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054–8.
6. Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160:369–79.
7. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932–54.
8. European Association for the Study of Liver Diseases. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392–420.
9. Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015; 7:51–70.
10. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023–8.
11. Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:714–25.
12. Wyles DL, Sulkowski MS, Dieterich D. Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy. Clin Infect Dis 2016; 63(suppl 1):3–11.
13. Denning J, Cornpropst M, Flach SD, Berrey MM, Symonds WT. Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother 2013; 57:1201–8.
14. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 2015; 54:677–90.
15. Sovaldi (sofosbuvir). Prescribing information. Foster City, CA: Gilead Sciences, 2015.
16. Harvoni (ledipasvir and sofosbuvir). Prescribing information. Foster City, CA: Gilead Sciences, 2015.
17. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015; 149:1315–7.
18. Kirby B, Mathias A, Rossi S, Moyer C, Shen G, Kearney B. No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, 2012.
19. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312:353–61.
20. Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015; 385:1098–106.
21. Zeuzem S, Hezode C, Bronowicki JP, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016; 64:292–300.
22. Daklinza (daclatasvir). Prescribing information. Princeton, NJ: Bristol-Myers Squibb, 2015.
23. Eley T, You X, Wang R, et al. Daclatasvir: overview of drug–drug interactions with antiretroviral agents and other common concomitant drugs. In: HIV DART, Miami, FL, 9–12 December 2014.
24. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013; 18:931–40.
25. Gandhi Y, Adamczyk R, Wang R, et al. Assessment of drug–drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ritonavir [abstract 80]. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 26–28 May 2015.
26. Song I, Jerva F, Zong J, et al. Evaluation and drug interactions between dolutegravir and daclatasvir in healthy volunteers [abstract 79]. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 26–28 May 2015.
27. Garimella T, Gandhi Y, Wang R, et al. Daclatasvir exposure alone does not explain HCV relapse in HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir with ritonavir-boosted darunavir in the ALLY-2 study [abstract 728]. In: AASLD LiverLearning, 14 November 2015; 109972.
28. Terrault N, Zeuzem S, Di Bisceglie A, et al. Treatment outcomes with 8, 12 and 24 week regimens of ledipasvir/sofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study. In: Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 13–17 November 2015.
29. Mascolini M. Impact of food and antacids on levels of ledipasvir and sofosbuvir. In: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 19–21 May 2014.
30. German P, Pang PS, Fang L, et al. Drug–drug interaction profile of the fixed dose combination tablet ledipasvir/sofosbuvir. In: American Association for the Study of Liver Diseases, Boston, MA, 7–11 November 2014.
31. Kirby B. Transporters: role in clinical development of HCV compounds. In: Presentation at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 19–21 May 2014.
32. German P, Pang PS, West S, et al. Drug interaction between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. In: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington, DC, 19–21 May 2014.
33. German P, Garrison K, Pang PS, et al. Drug interactions between the anti-HCV regimen ledipasvir/sofosbuvir and ritonavir boosted protease inhibitors plus emtricitabine/tenofovir DF. In: 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 23–26 February 2015.
34. Garrison KL, Custodi J, Pang PS, et al. Drug interactions between anti-HCV antivirals ledipasvir/sofosbuvir and integrase strand transfer inhibitor-based regimens [abstract 71]. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 26–28 May 2015.
35. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232–9.
36. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 373:705–13.
37. Olysio (simeprevir). Prescribing information. Titusville, NJ: Janssen Therapeutics, 2015.
38. Ouwerkerk-Mahadevan S, Alexandru S, Peeters M, et al. Summary of pharmacokinetic drug-drug interactions for simeprevir (TMC435), a hepatitis C virus Ns3/ 4A protease inhibitor. In: 14th European AIDS Conference, Brussels, Belgium, 16–19 October 2013.
39. Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. In: European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015.
40. Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. In: European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015.
41. Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015; 163:809–17.
42. Mogalian E, Lutz J, Osinusi A, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of sofosbuvir/velpatasvir fixed dose combination tablet. In: American Society for Clinical Pharmacology and Therapeutics, San Diego, CA, 8–12 March 2016.
43. Mathias A. Clinical pharmacology of DAAs for HCV: what’s new and what’s in the pipeline. In: 14th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, The Netherlands, 24 April 2013.
44. Mogalian E, German P, Kearney BP, et al. Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir. Clin Pharmacokinet 2015; 55:605–13.
45. Mogalian E, Mathias A, Brainard D, et al. The pharmacokinetics of GS-5816, a pan-genotypic HCV NS5A inhibitor, in HCV-uninfected subjects with moderate and severe hepatic impairment. J Hepatol 2014; 60:S317.
46. Mogalian E, Mathias A, Brainard D, et al. The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment. EASL–the International Liver Congress 2015. In: 50th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015.
47. Mogalian E, Stamm L, Osinusi A, et al. Drug-drug interaction studies between hepatitis C virus antivirals sofosbuvir and velpatasvir (GS-5816) and HIV antiretroviral therapies. In: 66th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, 13–17 November 2015.
48. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599–607.
49. Sulkowski M, Brau N, Lawitz E, et al. A randomized controlled trial of sofosbuvir/ velpatasvir fixed-dose combination for 12 weeks compared to sofosbuvir with ribavirin for 12 weeks in genotype 2 HCV-infected patients: the phase 3 ASTRAL-2 study. In: American Association for the Study of Liver Diseases, San Francisco, 13–17 November 2015.
50. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608–17.
51. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015; 373:2618–28.
52. Zepatier (elbasvir/grazoprevir). Prescribing information. Merck and Co, Inc, NJ: Whitehouse Station, 2016.
53. Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1–infected patients with Child-Pugh class B cirrhosis (C-SALT part A). In: 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015.
54. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386:1537–45.
55. Yeh W, Marshall W, Caro L, et al. Pharmacokinetic interaction of HCV NS5A inhibitor MK-8742 and ketoconazole in healthy subjects. In: 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 19–21 May 2014.
56. Caro L, Talaty J, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers [abstract 477]. Hepatology 2013;58(4 [suppl] AASLD Abstracts):437A.
57. Yeh W. Drug-drug interactions with grazoprevir/elbasvir: practical considerations for the care of HIV/HCV co-infected patients. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington, DC, 28 May 2015.
58. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015; 2:e319–27.
59. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087–97.
60. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). Prescribing information. North Chicago, IL: Abbvie, Inc, 2015.
61. Technivie (ombitasvir, paritaprevir, and ritonavir tablets). Prescribing information. North Chicago, IL: Abbvie, Inc, 2015.
62. Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the Ruby-I study. In: European Association for the Study of the Liver, Vienna, Austria, 22–26 April 2015.
63. Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63:20–9.
64. Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen). Antimicrob Agents Chemother 2015; 60:105–14.
65. Khatri A, Wang T, Wang H, et al. Drug-drug interactions of the direct-acting antiviral regimen of ABT-450/r, ombitasvir, and dasabuvir with emtricitabine + tenofovir, raltegravir, rilpivirine, and efavirenz [abstract 483]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, 5–9 September 2014.
66. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1:a randomized trial. JAMA 2015; 313:1223–31.
67. Werner JM, Serti E, Chepa-Lotrea X, et al. Ribavirin improves the IFN-gamma response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology 2014; 60:1160–9.
68. Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 2013; 23:1–12.
69. Li L, Koo SH, Limenta LM, et al. Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. J Clin Pharmacol 2009; 49:661–7.
70. Copegus (ribavirin). Prescribing information. South San Francisco, CA: Genentech, Inc, 2015.
71. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803–4.